CAR T-cell therapy for children with solid tumors
Part of Cancer, Digestive system, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a solid tumor that tests positive for a protein called GPC3
- Your child has tried at least two types of treatment (initial therapy and at least one salvage therapy) and the cancer has not responded or has come back
- Your child is at least 60% active and able to carry out daily activities (this is measured by a Lansky or Karnofsky score)
- Your child's organs (like liver, kidneys, heart) are working well enough for this treatment
- Your child has recovered from any side effects of previous treatments
- Your child does not have HIV, an active infection, or a history of organ transplantation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell (CAR T cell) that targets a protein called GPC3 found on certain solid tumors. It aims to see if these cells are safe and can help adults with liver cancer or other GPC3-positive tumors that have not responded to standard treatments.
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Hear when a new Solid Tumor (Excluding CNS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.